LixiLan tops Lantus in second Phase III

Zealand Pharma A/S (CSE:ZEAL) gained DKK23.50 (19%) to DKK145.50 on Monday after it and partner Sanofi (Euronext:SAN; NYSE:SNY) said LixiLan was superior to Lantus insulin glargine in the Phase III LixiLan-L trial to treat Type II diabetes. LixiLan combines the partners' lixisenatide and Sanofi's Lantus.

LixiLan met the primary endpoint of the 736-patient study, showing superiority to Lantus in reducing HbA1c after 30 weeks in diabetic patients whose disease was not controlled on basal insulin alone or combined with one or two anti-diabetic agents. The partners said LixiLan's safety profile was comparable to that of Lantus and lixisenatide. ...